Mostefa Bennamoun

Institute Mutualiste Montsouris — France

Medicine · Health Sciences

14h-index672citations141works0.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(79), Cancer Immunotherapy and Biomarkers(40), Renal and related cancers(21), Bladder and Urothelial Cancer Treatments(19), Prostate Cancer Treatment and Research(19)

Publications141 total

Figure S1 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Supplementary Tables TS1-23 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Figure S4 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Figure S8 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Figure S6 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Figure S3 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Figure S5 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Figure S2 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Figure S7 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Table S2 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
2025Open Access
Table S1 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
2025Open Access
Supplementary Figure Annotations from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
2025Open Access
Table S3 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
2025Open Access
Supplementary Figures from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
2025Open Access
Table S4 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
2025Open Access
Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer
BMC Cancer·2025· 2 citedOpen Access
OCTOPUS: A retrospective, multicenter study of real-world cabozantinib treatment of patients with advanced renal cell carcinoma in France—Subgroup analyses of treatment sequences and optimization.
Journal of Clinical Oncology·2025· 1 cited
Real world effectiveness of systemic treatment in patients (pts) with advanced upper tract urothelial carcinoma (UTUC) with histological variants.
Journal of Clinical Oncology·2025
Prognostic value of tumor regression grade (TRG) in patients with gastric/gastroesophageal junction cancer treated by peri-operative chemotherapy and surgery: A single-center experience (Institut Mutualiste Montsouris, Paris, France).
Journal of Clinical Oncology·2025
Supplementary Figures from Mesenchymal-like tumor cells and myofibroblastic cancer-associated fibroblasts are associated with progression and immunotherapy response of clear-cell renal cell carcinoma
2024Open Access
page 1 of 8Next →

Frequent Co-authors

Stéphane Oudard(22), Philippe Barthélémy(15), Yann Vano(13), Christine Chevreau(12), Virginie Verkarre(12), Wolf H. Fridman(12), Catherine Sautès‐Fridman(12), Cheng‐Ming Sun(10), Christophe Louvet(10), Réza Elaidi(9), Delphine Borchiellini(9), Xavier Cathelineau(8), Thibault Tricard(8), Alexandra Helleux(8), Véronique Lindner(8), Hervé Lang(8), Xiaoping Su(8), Irwin Davidson(8), Gabriel G. Malouf(8), David Fuks(8)